Checkpoint Inhibitor denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for checkpoint inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Your Checkpoint Inhibitor — Prior Authorization Required

UHC requires prior authorization for all checkpoint inhibitors. A "prior-auth-required" denial means either the drug was administered before authorization was obtained, the prior authorization request was submitted but was deemed incomplete, or the authorization lapsed and was not renewed before a new cycle of treatment. This is a process denial — it does not mean UHC has concluded the treatment is medically unnecessary — and it is among the most routinely reversed denial types when properly appealed.

For active cancer treatment, time matters: UHC is required by federal regulation to process expedited appeals within 72 hours, and you should invoke this at every stage.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial notice. Simultaneously invoke the expedited track given the oncology context.
• Retroactive PA request: If treatment has already been administered, file a retroactive prior-authorization request concurrently with the appeal. Document any clinical urgency that justified proceeding without advance authorization.
• ACA §2719 external review: Available after the internal process, within the ~4-month statutory window. An independent review organization will evaluate whether the treatment met medical-necessity criteria — a PA denial can be overturned on this basis even if the process objection stands.
• ERISA §503 (employer-sponsored plans): You are entitled to the full prior-authorization criteria applied, the specific reason for incompleteness or denial, and the complete administrative file.

## Documentation to Gather

1. Complete PA submission record: Confirm what was submitted and when — diagnosis, ICD-10 code, specific drug name, administration route, biomarker results, staging, line of therapy, and supporting clinical notes. 2. Prescriber medical-necessity letter: A detailed letter from the oncologist addressing each UHC prior-authorization criterion explicitly, with references to specific chart findings. 3. Biomarker and pathology records: PD-L1 expression, MSI/TMB status, genomic testing, and histology confirmation — these are typically required fields in UHC's PA criteria for checkpoint inhibitors. 4. Prior treatment documentation: Chart notes, infusion records, and response assessments for each prior line of therapy, establishing the treatment sequence. 5. UHC's PA criteria: Request the specific prior-authorization guidelines applied to this drug and indication. You are entitled to this under ERISA or ACA.

## Criteria-Mapping Structure

Obtain UHC's current prior-authorization policy for the specific checkpoint inhibitor. List each criterion and document the specific chart evidence that satisfies it: biomarker result with date, histology report, ECOG performance status, prior therapy history with outcomes. A structured point-by-point mapping eliminates the most common reason for PA denial (missing information) and gives the reviewer no basis to deny again on procedural grounds. If the original denial was for a specific documentation gap, address that gap first and directly.